More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

A newly issued report by the European Medicines Agency details an increase in inspections at active pharmaceutical ingredient (API) facilities as part of greater cooperation between European, US, and Australian regulatory authorities and the World...

Which drugs entering the market in 2018 are poised as blockbusters? DCAT Value Chain Insights examines the contenders launching this year. A recent analysis by Clarivate Analytics points to 12 drugs entering the market this year that are expected...

The USP, a standard-setting organization, has stated that that it will not develop a new monograph for a biologic unless there is stakeholder consensus supporting its creation, including support from the FDA. In making that decision, the USP...

How did the pharmaceutical industry perform in 2017, and what is the outlook for 2018 and beyond? Key for the industry is the performance of the US market, the largest national market in the global pharmaceutical industry, but what other factors...

An effective supply strategy is crucial for pharmaceutical companies, so what are the challenges that companies face? Managing risk, addressing shifts in product mix, and increasingly complex supply chains are some of the challenges. The DCAT Week...